Literature DB >> 25803383

Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations.

A Coulson1, A Levy1, M Gossell-Williams2.   

Abstract

Rituximab was the first chemotherapeutic monoclonal antibody (CmAb) approved for clinical use in cancer therapeutics in 1997 and has significantly improved the clinical outcomes in non-Hodgkin's lymphoma. Since then, numerous CmAbs have been developed and approved for the treatment of various haematologic and solid human cancers. In this review, the classification, efficacy and significantly reduced toxicity of CmAbs available for use in the United States of America are presented. Finally, the limitations of CmAbs and future considerations are explored.

Entities:  

Year:  2014        PMID： 25803383      PMCID： PMC4663950          DOI： 10.7727/wimj.2013.241

Source DB:  PubMed          Journal:  West Indian Med J        ISSN： 0043-3144            Impact factor:   0.171


  38 in total

Review 1.  Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.

Authors:  Martina Steiner; Dario Neri
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

Review 2.  Process economics of industrial monoclonal antibody manufacture.

Authors:  Suzanne S Farid
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-08-08       Impact factor: 3.205

Review 3.  Therapeutic potential of anticancer immunotoxins.

Authors:  Swati Choudhary; Mrudula Mathew; Rama S Verma
Journal:  Drug Discov Today       Date:  2011-04-12       Impact factor: 7.851

4.  Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.

Authors:  Feng Wen; Ruilei Tang; Yaxiong Sang; Meng Li; Qiancheng Hu; Zedong Du; Yi Zhou; Pengfei Zhang; Xiaofeng He; Qiu Li
Journal:  Cancer Sci       Date:  2013-07-30       Impact factor: 6.716

Review 5.  Antibody-drug conjugates for the treatment of cancer.

Authors:  John A Flygare; Thomas H Pillow; Paul Aristoff
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

Review 6.  Intricacies of bevacizumab-induced toxicities and their management.

Authors:  Sarah M Gressett; Sachin R Shah
Journal:  Ann Pharmacother       Date:  2009-03-03       Impact factor: 3.154

7.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

8.  Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.

Authors:  James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2007 Nov-Dec       Impact factor: 4.456

9.  Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab).

Authors:  Diane Seimetz
Journal:  J Cancer       Date:  2011-05-25       Impact factor: 4.207

10.  The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials.

Authors:  Jianlan Cui; Xueya Cai; Min Zhu; Tianshu Liu; Naiqing Zhao
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240
View more
  11 in total

Review 1.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

2.  Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.

Authors:  Hiroki Nakayama; Naoki Matsumaru; Katsura Tsukamoto
Journal:  Pharmaceut Med       Date:  2019-02

Review 3.  Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.

Authors:  Aswathy R Devan; Bhagyalakshmi Nair; Ayana R Kumar; Balachandran S Vinod; Lekshmi R Nath
Journal:  Mol Biol Rep       Date:  2021-10-20       Impact factor: 2.316

Review 4.  Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments.

Authors:  Alex J McCraw; Jitesh Chauhan; Heather J Bax; Chara Stavraka; Gabriel Osborn; Melanie Grandits; Jacobo López-Abente; Debra H Josephs; James Spicer; Gerd K Wagner; Sophia N Karagiannis; Alicia Chenoweth; Silvia Crescioli
Journal:  Cancers (Basel)       Date:  2021-09-04       Impact factor: 6.575

Review 5.  A Proposed Treatment Approach to Treat Lethal Mutating Cancers.

Authors:  Kevin Roe
Journal:  Pharm Res       Date:  2020-02-13       Impact factor: 4.200

Review 6.  Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma.

Authors:  Meng-Yu Wu; Tzu-Ting Lai; Wan-Ting Liao; Chia-Jung Li
Journal:  Ther Adv Med Oncol       Date:  2020-06-08       Impact factor: 8.168

Review 7.  Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.

Authors:  Meher Un Nessa; Md Atiar Rahman; Yearul Kabir
Journal:  Biomed Res Int       Date:  2020-08-24       Impact factor: 3.411

Review 8.  Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients.

Authors:  Francesco Sabbatino; Valeria Conti; Luigi Liguori; Giovanna Polcaro; Graziamaria Corbi; Valentina Manzo; Vincenzo Tortora; Chiara Carlomagno; Carmine Vecchione; Amelia Filippelli; Stefano Pepe
Journal:  Life (Basel)       Date:  2021-01-30

Review 9.  The Epithelial-Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment.

Authors:  Yunpeng Bai; Jingjing Sha; Tatsuo Okui; Ichiro Moriyama; Huy Xuan Ngo; Hiroto Tatsumi; Takahiro Kanno
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

10.  Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer.

Authors:  Heng Liang Tan; Charlene Yong; Bao Zhu Tan; Wey Jia Fong; Jayanthi Padmanabhan; Angela Chin; Vanessa Ding; Ally Lau; Lu Zheng; Xuezhi Bi; Yuansheng Yang; Andre Choo
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.